Needham Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $4
I-Mab Price Target Maintained With a $4.00/Share by Needham
I-MAB Analyst Ratings
HC Wainwright & Co. Maintains Buy on I-MAB, Lowers Price Target to $7
Promising Pipeline and Strong Financial Position Drive Buy Rating for I-Mab
Brookline Capital Initiates I-Mab(IMAB.US) With Buy Rating, Announces Target Price $6
I-Mab Initiated With a Buy at Brookline
Needham Maintains I-Mab(IMAB.US) With Buy Rating, Cuts Target Price to $4
I-Mab Maintains Buy Rating Amid Strategic Refocus on Givastomig and Financial Stability
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress
I-MAB Analyst Ratings
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
I-MAB Analyst Ratings
I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline
I-MAB Analyst Ratings
I-MAB Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
I-MAB Analyst Ratings